A Multiparametric Serum Marker Panel as a Complementary Test to Mammography for the Diagnosis of Node-Negative Early-Stage Breast Cancer and DCIS in Young Women

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Epidemiology, Biomarkers and Prevention

• Publication date

  2014-06-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1055-9965.EPI-14-0267PMID 24957886
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of Screening Whole-Breast Sonography as a Supplemental Tool in Conjunction With Mammography in Women With Dense Breasts: Chae EY, Kim HH, Cha JH, et al (Univ of Ulsan, College of Medicine, Seoul, Korea) J Ultrasound Med 32:1573-1578, 2013§

  2014cited by this paper
• Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis

  2014cited by this paper
• Breast cancer detected with screening US: reasons for nondetection at mammography.

  2014cited by this paper
• Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer

  2013cited by this paper
• Early life factors and adult mammographic density

  2013cited by this paper
• Combined measurement of CA 15-3 with novel autoantibodies improves diagnostic accuracy for breast cancer

  2013cited by this paper
• Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early‐stage breast cancers

  2013cited by this paper
• Improvement of protein immobilization for the elaboration of tumor-associated antigen microarrays: application to the sensitive and specific detection of tumor markers from breast cancer sera.

  2013cited by this paper
• Molecular Diagnostics

  2013cited by this paper
• Possible influence of mammographic density on local and locoregional recurrence of breast cancer

  2013cited by this paper
• Evaluation of Screening Whole‐Breast Sonography as a Supplemental Tool in Conjunction With Mammography in Women With Dense Breasts

  2013cited by this paper
• Effect of three decades of screening mammography on breast-cancer incidence.

  2012cited by this paper
• High-resolution diffusion-weighted magnetic resonance imaging in patients with locally advanced breast cancer.

  2012influential reference
• Evaluation of Known Oncoantibodies, HER2, p53, and Cyclin B1, in Prediagnostic Breast Cancer Sera

  2012cited by this paper
• Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk.

  2012cited by this paper
• The current status of cancer biomarker research using tumour-associated antigens for minimal invasive and early cancer diagnostics.

  2012cited by this paper
• Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer

  2012cited by this paper
• Alpha 1‐antitrypsin: A novel tumor‐associated antigen identified in patients with early‐stage breast cancer

  2012cited by this paper
• SOX2 Autoantibodies As Noninvasive Serum Biomarker for Breast Carcinoma

  2012cited by this paper
• The negative predictive value of breast Magnetic Resonance Imaging in noncalcified BIRADS 3 lesions.

  2012cited by this paper
• The influence of mammogram acquisition on the mammographic density and breast cancer association in the mayo mammography health study cohort

  2012cited by this paper
• Quantification of EGFR autoantibodies in the amplification phenomenon of HER2 in breast cancer

  2011cited by this paper
• Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis

  2011cited by this paper
• Role of MRI (magnetic resonance imaging) versus conventional imaging for breast cancer presurgical staging in young women or with dense breast.

  2011cited by this paper
• Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program.

  2011cited by this paper
• Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer.

  2011cited by this paper
• Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer

  2011cited by this paper
• Identifying women at risk of delayed breast cancer diagnosis.

  2011cited by this paper
• Overdiagnosis in cancer.

  2010cited by this paper
• Detection of Circulating Anti-Mucin 1 (MUC1) Antibodies in Breast Tumor Patients by Indirect Enzyme-Linked Immunosorbent Assay Using a Recombinant MUC1 Protein Containing Six Tandem Repeats and Expressed in Escherichia coli

  2010cited by this paper
• Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients

  2010cited by this paper
• Breast cancers not detected at MRI: review of false-negative lesions.

  2010cited by this paper
• Delayed diagnosis of breast cancer in women recalled for suspicious screening mammography.

  2009cited by this paper
• Sperm-Associated Antigen 9, a Novel Biomarker for Early Detection of Breast Cancer

  2009cited by this paper
• Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women

  2009cited by this paper
• Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis

  2009cited by this paper
• Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations.

  2008cited by this paper
• Autoantibodies as potential biomarkers for breast cancer

  2008cited by this paper
• Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer.

  2008cited by this paper
• A human monoclonal autoantibody to breast cancer identifies the PDZ domain containing protein GIPC1 as a novel breast cancer-associated antigen

  2008cited by this paper
• Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera.

  2008cited by this paper
• Autoantibody to Tumor Antigen, Alpha 2-HS Glycoprotein: A Novel Biomarker of Breast Cancer Screening and Diagnosis

  2008cited by this paper
• Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ.

  2008cited by this paper
• Breast cancer in young women.

  2008cited by this paper
• Beyond standard mammographic screening: mammography at age extremes, ultrasound, and MR imaging.

  2007cited by this paper
• Autoantibodies in breast cancer: their use as an aid to early diagnosis.

  2007cited by this paper
• Analysis of patients with false negative mammography and symptomatic breast carcinoma

  2007cited by this paper
• Erratum: Autoantibodies to annexin XI-A and other autoantigens in the diagnosis of breast cancer (Cancer Research (2004) 64 (5089-5096))

  2006cited by this paper
• Evaluating new screening tests for breast cancer

  2006cited by this paper
• Imaging the young breast.

  2006cited by this paper
• Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial.

  2006cited by this paper
• Screening women at high risk for breast cancer with mammography and magnetic resonance imaging

  2005cited by this paper
• Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis.

  2005cited by this paper
• Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).

  2005cited by this paper
• The role of anti-CENP-B and anti-SS-B antibodies in breast cancer.

  2005cited by this paper
• Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis.

  2005cited by this paper
• Magnetic resonance imaging of the breast prior to biopsy.

  2004cited by this paper
• Probabilities of death from breast cancer and other causes among female breast cancer patients.

  2004cited by this paper
• Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer.

  2004cited by this paper
• Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer

  2004cited by this paper
• Breast density as a determinant of interval cancer at mammographic screening

  2004cited by this paper
• Normal mammography and ultrasonography in the setting of palpable breast cancer.

  2003cited by this paper
• Individual and Combined Effects of Age, Breast Density, and Hormone Replacement Therapy Use on the Accuracy of Screening Mammography

  2003cited by this paper
• Interval breast cancers in New South Wales, Australia, and comparisons with trials and other mammographic screening programmes

  2002cited by this paper
• False-negative breast screening assessment: what lessons can we learn?

  2001cited by this paper
• Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast

  1999cited by this paper
• Breast cancer in young women.

  1979cited by this paper

• Predicting tuberculosis progression in school contacts: novel host biomarkers for early risk assessment

  2025cites this paper
• Autoantibodies as biomarkers for breast cancer diagnosis and prognosis

  2022cites this paper
• Can serum autoantibodies be a potential early detection biomarker for breast cancer in women? A diagnostic test accuracy review and meta-analysis

  2021cites this paper
• High‐throughput and multi‐phases identification of autoantibodies in diagnosing early‐stage breast cancer and subtypes

  2021cites this paper
• Autoantibodies in Early Detection of Breast Cancer

  2020cites this paper
• Endocrine-Disrupting Chemicals’ (EDCs) Effects on Tumour Microenvironment and Cancer Progression: Emerging Contribution of RACK1

  2020cites this paper
• Application and Analysis of Biomedical Imaging Technology in Early Diagnosis of Breast Cancer.

  2020cites this paper
• OXER1 and RACK1-associated pathway: a promising drug target for breast cancer progression

  2020cites this paper
• Ribosomes as a nexus between translation and cancer progression: Focus on ribosomal Receptor for Activated C Kinase 1 (RACK1) in breast cancer

  2020cites this paper
• Hsp60 in Cancer Immunity: Biological Basis, Diagnostic Potential and Therapeutic Opportunities

  2019cites this paper
• Telomerase and Telomeres in Endometrial Cancer

  2019cites this paper
• CMAR_A_229389 9685..9699

  2019cites this paper
• The Prognosis Of Peroxiredoxin Family In Breast Cancer

  2019cites this paper
• Endometrial Cancer: From Biological to Clinical Approaches

  2019cites this paper
• IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer

  2018cites this paper
• Tissue‐based quantitative proteomics to screen and identify the potential biomarkers for early recurrence/metastasis of esophageal squamous cell carcinoma

  2018cites this paper
• Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma

  2017cites this paper
• The Role of Pontin and Reptin in Cellular Physiology and Cancer Etiology

  2017cites this paper
• Panel of SEREX-defined antigens for breast cancer autoantibodies profile detection

  2017cites this paper
• Breast cancer cases of female patients under 35 years of age in Togo: A series of 158 cases.

  2017cites this paper
• Crucial considerations for pipelines to validate circulating biomarkers for breast cancer

  2016cites this paper
• Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study

  2015cites this paper